Monitor the company's quarterly filings for actual repurchase execution under this authorization and the completion of the existing ASR. The $2.0 billion authorization signals management's view that shares are undervalued, but the discretionary nature means execution pace will depend on market conditions and alternative capital uses.
Price Chart
Executive Summary
United Therapeutics announced a $2.0 billion share repurchase authorization, effective through October 21, 2027. The company also has an ongoing accelerated share repurchase (ASR) transaction from September 2026 that will not reduce the new authorization. This is a capital allocation signal reflecting management's confidence in the company's balance sheet and free cash flow.
Key Facts
- Board approved up to $2.0 billion in share repurchases on October 21, 2026
- Authorization is valid for one year, through October 21, 2027
- Company has an ongoing ASR transaction from September 2026 under a prior authorization
- ASR scheduled to terminate in Q4 2026 and does not reduce the new $2.0 billion authorization
- Repurchases may be executed via ASR, open market, or privately negotiated transactions
- No minimum purchase obligation; program is discretionary
Financial Impact
$2.0 billion share repurchase authorization, representing a significant capital return commitment. No actual repurchases have been executed under this new program.
Risk Factors
- Authorization does not obligate the company to repurchase any shares
- Execution depends on market conditions and alternative capital uses
- Ongoing ASR may affect near-term share count dynamics
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-117964 |
| Document: tm2628087d1_ex99-1.htm | 0001104659-26-117964 |
| Document: 0001104659-26-117964-index-headers.html | 0001104659-26-117964 |
| Document: 0001104659-26-117964-index.html | 0001104659-26-117964 |
| Document: 0001104659-26-117964.txt | 0001104659-26-117964 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | Insider Cluster | $592.84 | awaiting T+5 | — | $591.20 (−0.28%) |
Oct 22, 2026 5d ago | 8-K | $584.79 | awaiting T+5 | — | $591.20 (+1.10%) |
Oct 22, 2026 6d ago | Insider Cluster | $587.50 | awaiting T+5 | — | $591.20 (−0.63%) |
Oct 21, 2026 6d ago | Insider Cluster | $584.79 | awaiting T+5 | — | $591.20 (+1.10%) |
Oct 20, 2026 7d ago | Insider Cluster | $563.49 | awaiting T+5 | — | $591.20 (+4.92%) |
Oct 19, 2026 9d ago | Insider Cluster | $553.88 $591.20 | ▲ +6.74% | ▲ +6.66% | $591.20 (+6.74%) |
Oct 16, 2026 11d ago | Insider Cluster | $543.15 $592.84 | ▲ +9.15% | ▲ +9.29% | $591.20 (+8.85%) |
Oct 14, 2026 13d ago | 8-K | $540.03 $563.49 | ▲ +4.34% | ▲ +3.89% | $591.20 (+9.48%) |
Oct 5, 2026 22d ago | Insider Cluster | $541.62 $543.40 | ▼ −0.33% | ▼ −0.47% | $591.20 (−9.15%) |
Oct 2, 2026 25d ago | Insider Cluster | $536.40 $550.10 | ▲ +2.55% | ▲ +2.13% | $591.20 (+10.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers